Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Li Gobbi

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Journal of Personalized Medicine|February 26, 2026
Factors Associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA): Real-World Evidence from a Single-Center Cross-Sectional StudyMaurizio Benucci, Francesca Li Gobbi, Emanuele Antonio Maria Cassarà, et al.
Frontiers in Medicine|March 17, 2022
Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response?Maurizio Benucci, Arianna Damiani, Maria Infantino, et al.
Journal of Personalized Medicine|September 28, 2023
ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical PracticeMaurizio Benucci, Marco Bardelli, Massimiliano Cazzato, et al.
Journal of Personalized Medicine|July 27, 2024
Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65)Maurizio Benucci, Marco Bardelli, Massimiliano Cazzato, et al.
Biologics : Targets & Therapy|April 5, 2016
Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumabMaurizio Benucci, Francesca Meacci, Valentina Grossi, et al.
The Journal of Infection|October 30, 2012
Serial QuantiFERON TB-gold in-tube testing during LTBI therapy in candidates for TNFi treatmentFilippo Bartalesi, Delia Goletti, Michele Spinicci, et al.
Immunological Investigations|July 13, 2019
The Laboratory Role in anti-TNF Biological Therapy EraValentina Grossi, Francesca Gulli, Maria Infantino, et al.
Clinical and Experimental Medicine|February 5, 2025
Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre studyCaterina Baldi, Stefano Gentileschi, Francesca Li Gobbi, et al.
Biomedicines|March 29, 2023
The Third Dose of BNT162b2 COVID-19 Vaccine Does Not "Boost" Disease Flares and Adverse Events in Patients with Rheumatoid ArthritisAndrea Picchianti Diamanti, Assunta Navarra, Gilda Cuzzi, et al.
Seminars in Arthritis and Rheumatism|November 27, 2015
Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritisFabrizio Cantini, Laura Niccoli, Carlotta Nannini, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Journal of Personalized Medicine|February 26, 2026
Factors Associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA): Real-World Evidence from a Single-Center Cross-Sectional StudyMaurizio Benucci, Francesca Li Gobbi, Emanuele Antonio Maria Cassarà, et al.
Frontiers in Medicine|March 17, 2022
Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response?Maurizio Benucci, Arianna Damiani, Maria Infantino, et al.
Journal of Personalized Medicine|September 28, 2023
ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical PracticeMaurizio Benucci, Marco Bardelli, Massimiliano Cazzato, et al.
Journal of Personalized Medicine|July 27, 2024
Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65)Maurizio Benucci, Marco Bardelli, Massimiliano Cazzato, et al.
Biologics : Targets & Therapy|April 5, 2016
Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumabMaurizio Benucci, Francesca Meacci, Valentina Grossi, et al.
The Journal of Infection|October 30, 2012
Serial QuantiFERON TB-gold in-tube testing during LTBI therapy in candidates for TNFi treatmentFilippo Bartalesi, Delia Goletti, Michele Spinicci, et al.
Immunological Investigations|July 13, 2019
The Laboratory Role in anti-TNF Biological Therapy EraValentina Grossi, Francesca Gulli, Maria Infantino, et al.
Clinical and Experimental Medicine|February 5, 2025
Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre studyCaterina Baldi, Stefano Gentileschi, Francesca Li Gobbi, et al.
Biomedicines|March 29, 2023
The Third Dose of BNT162b2 COVID-19 Vaccine Does Not "Boost" Disease Flares and Adverse Events in Patients with Rheumatoid ArthritisAndrea Picchianti Diamanti, Assunta Navarra, Gilda Cuzzi, et al.
Seminars in Arthritis and Rheumatism|November 27, 2015
Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritisFabrizio Cantini, Laura Niccoli, Carlotta Nannini, et al.
Pageof 7